Contribution of Bone Marrow-Derived Hematopoietic Stem/Progenitor Cells to the Generation of Donor-Marker+ Cardiomyocytes In Vivo

Mitsuhiro Fukata1*, Fumihiko Ishikawa1,2*, Yuho Najima2, Takuji Yamauchi1, Yoriko Saito2, Katsuto Takenaka1, Kohta Miyawaki1, Hideki Shimazu1, Kazuya Shimoda3, Takaaki Kanemaru4, Kei-ichiro Nakamura6, Keita Odashiro1, Koji Nagafuji6, Mine Harada1, Koichi Akashi1,7

1 Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan, 2 Laboratory for Human Disease Models, RIKEN Research Center for Allergy and Immunology, Yokohama, Japan, 3 Department of Gastroenterology and Hematology, Faculty of Medicine, Miyazaki University, Miyazaki, Japan, 4 Morphology Core, Kyushu University, Fukuoka, Japan, 5 Second Department of Anatomy, Kurume University School of Medicine, Kurume, Japan, 6 Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan, 7 Center for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka, Japan

Abstract

Background: Definite identification of the cell types and the mechanism relevant to cardiomyogenesis is essential for effective cardiac regenerative medicine. We aimed to identify the cell populations that can generate cardiomyocytes and to clarify whether generation of donor-marker+ cardiomyocytes requires cell fusion between BM-derived cells and recipient cardiomyocytes.

Methodology/Principal Findings: Purified BM stem/progenitor cells from green fluorescence protein (GFP) mice were transplanted into C57BL/6 mice or cyan fluorescence protein (CFP)-transgenic mice. Purified human hematopoietic stem cells (HSCs) from cord blood were transplanted into immune-compromised NOD/SCID/IL2r-null mice. GFP+ cells in the cardiac tissue were analyzed for the antigenecity of a cardiomyocyte by confocal microscopy following immunofluorescence staining. GFP+ donor-derived cells, GFP+ CFP+ fused cells, and GFP+ recipient-derived cells were distinguished by linear unmixing analysis. Hearts of xenogeneic recipients were evaluated for the expression of human cardiomyocyte genes by real-time quantitative polymerase chain reaction. In C57BL/6 recipients, Lin−/lowCD45− hematopoietic cells generated greater number of GFP+ cardiomyocytes than Lin−/lowCD45− mesenchymal cells (37.0+/−23.9 vs 0.00+/−0.00 GFP+ cardiomyocytes per a recipient, P = 0.0095). The number of transplanted purified HSCs (Lin−/lowSca-1+ or Lin−/lowC-Kit+ or CD34−/lowSca-1−/lowC-Kit−) showed correlation to the number of GFP+ cardiomyocytes (R = 0.05 in each cell fraction), and the incidence of GFP+ cardiomyocytes per injected cell dose was greatest in CD34−Lin−/lowSca-1−/lowC-Kit− recipients. Of the hematopoietic progenitors, total myeloid progenitors generated greater number of GFP+ cardiomyocytes than common lymphoid progenitors (12.8+/−10.7 vs 0.67+/−1.00 GFP+ cardiomyocytes per a recipient, P = 0.0021). In CFP recipients, all GFP+ cardiomyocytes examined coexpressed CFP. Human troponin C and myosin heavy chain 6 transcripts were detected in the cardiac tissue of some of the xenogeneic recipients.

Conclusions/Significance: Our results indicate that HSCs resulted in the generation of cardiomyocytes via myeloid intermediates by fusion-dependent mechanism. The use of myeloid derivatives as donor cells could potentially allow more effective cell-based therapy for cardiac repair.

Introduction

Modification of regenerative capacity in injured heart could be potentially alternative to conventional therapy for treating patients suffering from heart failure [1–7]. Based on the promising results in rodents [3,4], clinical trials of cellular therapy using bone marrow (BM) cells for ischemic heart disease patients have been designed. In many of clinical trials for improving the function of cardiac recovery, some favorable results were obtained following injection of BM mononuclear cells (MNCs) [2,5–7]. However, careful examination needs to be performed in basic research because cell fate and the effects of transplanted cells are not fully unveiled [8].

BM contains heterogeneous cell populations including at least two distinct stem cells, hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) [9], and various progenitors of myeloid and lymphoid lineages. Both HSCs and MSCs have been reported to acquire the phenotype of cardiomyocytes in syngeneic
or xenogeneic recipients [4,10–13]. However, quantitative analysis of regenerative capacity by each stem fraction has not been performed in the identical transplantation setting.

One proposed mechanism for the phenotypic change of BM-derived cells to tissue-specific cells is cell fusion. Since the original report of spontaneous cell fusion between BM cells and embryonic stem cells [14], it has become apparent that not only some BM-derived cells in the heart and other selective tissues are the consequences of cell fusion at least in part [10,12,15], but also fused BM-derived cells can be reprogrammed to express tissue specific genes [16,17]. On the other hand, BM cells have been reported to generate non-hematopoietic cells in certain tissues without fusion requirement [18,19] although cell fate conversion from HSCs themselves directly to cardiomyocytes has questioned in several studies [10,20,21].

To improve the efficiency of cardiac functional restoration and to minimize adverse effects of cell-based therapy using BM cells, the cell type with the greatest contribution to cardiomyogenesis and mechanisms underlying altered cardiac function need to be clarified in vivo. In this study, we examined cardiomyogenic potential of BM cells following syngeneic BM transplantation to identify the cell population in BM that possesses cardiomyogenic potential and to clarify whether cardiomyogenesis by BM-derived cells require cell fusion with recipient cardiomyocytes. Furthermore, we adopted xenogeneic transplantation system to unveil genetic sequences of donor-derived cardiomyocytes through discrimination of the donor gene from the recipient gene. To fully exploit the capacity of stem cells, we employed newborns as recipients, in which age-related decline of regenerative capacity can be restored by environmental factors [22].

Results

Determination of Cell Fate in Cardiac Tissue of Recipient Mice Transplanted with Syngeneic BM Cells

We first created an in vivo model for evaluating cell fate of BM cells in cardiac tissue by injecting $10^7$ unfractionated green fluorescence protein (GFP) mouse BM cells into irradiated newborn C57BL/6 mice, followed by ventricular puncture. In the recipients, we detected GFP+ cells preferentially located adjacent to the injured sites. GFP+ cells in recipient cardiac tissues included CD45+ or CD11b+ hematopoietic cells (Figure 1A), vimentin+ fibroblasts (Figure 1B), cardiac troponin I (TnI)+ and/or Connexin 43 (Cx43)+ cardiomyocytes (Figure 1C and 1D) indicating that the system could be used for analyzing differentiative and regenerative properties of donor stem/progenitor cells. Cardiomyocytes were counted by their specific intracellular striated structure and longer diameter compared with hematopoietic cells. Immunofluorescence studies confirmed that the counted cells were cardiomyocytes as evidenced by the expression of TnI. Since the frequencies of GFP+ cardiomyocytes were similar in recipients transplanted with total BM cells or in those transplanted with Lin−/low MNCs, we postulated that the cardiomyogenic cells in BM are enriched in immature Lin−/low MNCs.

BM-derived Cardiomyocytes Originate from the Hematopoietic Lineage

We next determined the contribution of HSCs and MSCs, two already-defined stem cells in BM, to the generation of GFP+ cardiomyocytes. Multi-lineage differentiation capacities of HSCs included in the CD45+ fraction and MSCs included in the CD15+ fraction were confirmed by the development of lymphoid and myeloid cells in vivo and the induction of osteoblasts and adipocytes in vitro and in vivo, respectively (see Figure S1). To compare the cardiomyogenic abilities, $1.8 \times 10^5$–$4.4 \times 10^7$ Lin−/lowCD45+ cells and $3.6 \times 10^5$–$2.5 \times 10^7$ Lin−/lowCD45− cells from GFP mice were transplanted into syngeneic recipients. At 4–6 weeks after transplantation, GFP+ cardiomyocytes were detected only in recipients transplanted with Lin−/lowCD45+ cells (n = 6). By contrast, GFP+ cardiomyocytes were not detected in recipients transplanted with Lin−/lowCD45− cells (n = 4; P = 0.0095 Lin−/lowCD45+ versus Lin−/lowCD45−; Table 1) nor in the recipient with purified GFP+Lin−/CD45− cells. These findings suggest that donor-derived cardiomyocytes following BM transplantation originate from the hematopoietic lineage at least in this transplantation setting.

Transplantation of Purified BM HSC Fraction Resulted in the Efficient Production of Donor-derived Cardiomyocytes

Next, we aimed to assess the cardiomyogenic ability of purified hematopoietic stem/progenitor population. We transplanted limiting numbers of GFP+Lin−/lowSca-1+ cells including HSCs and hematopoietic progenitors, purified GFP+Lin−/lowSca-1+c-Kit− cells (LSKs; Figure 2A) including HSCs and multipotent progenitors, and purified GFP+CD34+ Lin−/lowSca-1+c-Kit− cells (CD34+ LSKs; Figure 2A) which contain HSCs that have long-term self-renewing potential. In all recipients transplanted with above three types of cells, GFP+ cells of myeloid lineage, B cell lineage, and T cell lineage were present in peripheral blood (PB) and BM (see Figure S2). The numbers of GFP+ cardiomyocytes significantly correlated with the injected cell dose in each group of the recipients transplanted with $10^5$–$10^6$ Lin−/lowSca-1+ cells from GFP mice, $10^3$–$10^5$ GFP+LSKs, and 1–$10^6$ GFP+CD34+ LSKs (P < 0.05 in all groups; Figure 2C–E, Table 1). Furthermore, the incidence of GFP+ cardiomyocytes per injected cell dose was greatest in GFP+CD34+ LSKs recipients followed by that in GFP+LSKs recipients, and the incidence in GFP+Lin−/lowSca-1+ recipients was the lowest (Figure 2F, Table 1). GFP+ cardiomyocytes were detected following transplantation of as few as 10 GFP+CD34+ LSKs. We further confirmed contribution of self-renewing HSCs to the generation of cardiomyocytes by secondary and tertiary BM transplantation from GFP+LSK recipients (see Table S1). These findings indicate that BM cells with cardiomyogenic capacity are highly enriched within the CD34+ LSK HSC population.

Myeloid Lineage Cells are the Primary Intermediates for Generating Cardiomyocytes

Since the capacity of HSCs to convert directly into cardiomyocytes has yet to be determined [18–21], we examined the capacity of hematopoietic progenitors to act as relevant intermediates for cardiomyogenesis. At 4 weeks after transplantation of $1.2 \times 10^5$–$1.4 \times 10^6$ fluorescence-activated cell sorting (FACS)-purified GFP+Lin−/Thy1.2+Sca-1−c-Kit−/low cells which mainly contain mixed myeloid and lymphoid progenitor population, GFP+ cardiomyocytes were identified in all recipients (n = 10; Table 1). This result indicates that transplanted HSCs give rise to cardiomyocytes via hematopoietic intermediates, at least partly.

To discriminate the hematopoietic lineage required in cardiomyogenesis, we then transplanted $0.4–2.3 \times 10^5$ FACS-purified GFP+Lin−/Thy1.2 interleukin-7 receptor α-chain (IL-7Rαz) Sca-1−c-Kit−/low antibody cells which mainly contain mixed myeloid and lymphoid progenitor population, GFP+ cardiomyocytes were identified in all recipients (n = 7; Table 1). This result indicates that transplanted HSCs give rise to cardiomyocytes via hematopoietic intermediates, at least partly.
myeloid engraftment while recipients of CLPs showed predominant GFP\(^+\) lymphoid engraftment in PB (see Figure S2). Although recipients of myeloid progenitors and CLPs showed similar PB GFP\(^+\) engraftment (Table 1), significantly greater number of GFP\(^+\) cardiomyocytes were identified in recipients transplanted with myeloid progenitors than in those transplanted with CLPs (P = 0.0021; Table 1). We further confirmed the contribution of myeloid cells to the generation of cardiomyocytes by transplantation of GFP\(^+\)Lin^IL-7R^Sca-1^c-Kit^Fcy receptor-II/III^ (Fc\(\gamma\)R\(^{low}\)-CD34\(^+\) common myeloid progenitor (CMPs; 0.3–1.0 \times 10^5, n = 6; Table 1) and GFP\(^+\)Lin^IL-7R^Sca-1^c-Kit^FcyR\(^{high}\)-CD34\(^+\) granulocyte/monocyte progenitors (GMPs;
Table 1. The number of donor-derived cardiomyocytes after transplantation of purified BM cells.

| Donor cell type | Cell dose | n | Days after injection | BM %GFP* | PB %GFP* | GFP+ cardiomyocytes* |
|-----------------|-----------|---|----------------------|----------|----------|---------------------|
| Hematopoietic cell | Lin2/Sca-1+/+/CD45+ | 0.2–4.4 x 10^7 | 6 | 25–46 | 86.7+/-13.9 | 90.6+/-5.6 | 37.0+/-23.9 |
| Mesenchymal cell | Lin2/Sca-1+/+CD45+ | 0.4–2.5 x 10^6 | 4 | 25–39 | 0.35+/-0.39 | 0.03+/-0.05 | 0.00+/-0.00 |
| HSC | Lin2/Sca-1+/+ | 10^6 | 6 | 29–34 | 83.2+/-6.6 | 96.4+/-2.9 | 33.9+/-16.0 |
| | | | 5 | 29–39 | 54.8+/-17.8 | 75.5+/-17.0 | 21.8+/-10.7 |
| | | | 10^6 | 5 | 28–39 | 3.0+/-1.6 | 6.0+/-7.6 | 4.2+/-3.4 |
| | | | 10^6 | 5 | 28–39 | 0.59+/-0.40 | 1.6+/-2.5 | 1.2+/-1.1 |
| LSK | Lin2/Sca-1+/+Cy3 | 1.0–1.8 x 10^5 | 6 | 27–44 | 76.6+/-17.7 | 89.1+/-17.0 | 33.6+/-43.1 |
| | | | 1.0–4.0 x 10^4 | 31–52 | 36.2+/-25.1 | 45.0+/-32.8 | 9.3+/-10.3 |
| | | | 1.0–2.0 x 10^3 | 31–52 | 25.5+/-23.3 | 38.2+/-27.6 | 2.4+/-2.0 |
| CD34+ LSK | Lin2/Sca-1+/+ | 10^5 | 2 | 28–50 | 66.8+/-27.3 | 67.3+/-23.6 | 12.5+/-5.0 |
| | | | 10^4 | 3 | 31–57 | 6.7+/-10.9 | 15.5+/-14.9 | 3.4+/-2.5 |
| | | | 10 | 7 | 213–354 | 0.19+/-0.13 | 0.05+/-0.05 | 0.14+/-0.38 |
| | | | 1 | 34 | 116–378 | 0.12+/-0.21 | 0.06+/-0.09 | 0.00+/-0.00 |
| Hematopoietic progenitor | Lin2/Sca-1+/+/Thy1.2+/+/c-kit+/+/ | 1.2–1.4 x 10^6 | 3 | 29–31 | 62.9+/-18.7 | 82.3+/-4.4 | 16.9+/-8.2 |
| | | | 1.2–4.7 x 10^5 | 3 | 27–29 | 37.9+/-21.3 | 51.8+/-27.5 | 14.4+/-7.4 |
| | | | 1.2–3.0 x 10^4 | 4 | 21–29 | 4.6+/-5.3 | 3.8+/-2.4 | 10.8+/-4.4 |
| Myeloid progenitor | Lin2/Sca-1+/+/c-kit+/low | 0.4–2.8 x 10^5 | 7 | 24–39 | 4.2+/-5.2 | 3.6+/-4.1 | 12.8+/-10.2 |
| | | | 0.3–1.0 x 10^5 | 6 | 31–42 | 0.87+/-0.70 | 0.52+/-0.59 | 17.2+/-7.3 |
| | | | 0.9–1.3 x 10^5 | 4 | 24–42 | 1.5+/-2.4 | 11.0+/-22.0 | 6.6+/-5.9 |
| | | | 0.2–3.3 x 10^5 | 9 | 24–39 | 4.0+/-4.7 | 8.7+/-6.8 | 0.67+/-1.00 |

*P = 0.0095 by Mann-Whitney U test, Lin2/Sca-1+/+/CD45+ versus Lin2/Sca-1+/+CD45+.
**P = 0.0021 by Mann-Whitney U test, Myeloid progenitor versus CLP.
***P = 0.0004 by Mann-Whitney U test, CMP versus CLP.
****P = 0.1142 by Mann-Whitney U test, Myeloid progenitor versus CLP.
*GFP+ cardiomyocytes were counted in 40 contiguous sections from apex of the heart per a mouse. Detailed information of histological analysis is described in Materials and Methods, Materials and Methods S1.
Abbreviations: BM: bone marrow, PB: peripheral blood, HSC: hematopoietic stem cell, LSK: Lin2/Sca-1+/+, CMP: common myeloid progenitor, GMP: granulocyte/macrophage progenitor, CLP: common lymphoid progenitor.

doi:10.1371/journal.pone.0062506.t001

0.9–1.3 x 10^5, n = 4; Table 1). These findings suggest that myeloid derivatives are responsible for providing cardiomyocytes in recipients.

Cell Fusion is the Major Mechanism Underlying the Generation of BM-derived Cardiomyocytes

To explore the mechanism of BM-derived cardiomyocyte generation, BM cells of GFP mice were transplanted into cyan fluorescence protein (CFP)-transgenic newborn mice. At 4–22 weeks after transplantation of unfractionated BM cells, LSK, Lin2/Sca-1+/+ c-kit+/low, Lin2/Sca-1+ and Lin2/Sca-1+ cells from GFP mouse BM, 1–166 GFP+ cardiomyocytes per a mouse were detected in CFP recipients (n = 11). The incidence of GFP+ cardiomyocytes in CFP recipients was comparable to that in C57BL/6 recipients, suggesting that the cardiomyogenic event is not influenced by employing CFP-transgenic mice as recipients. The emitted fluorescence from recipient cardiac sections stained with cardiac TnI-cyanin-3 (Cy3), Cx43-cyanin-5 (Cy5), and 4’-diethylamino-2-phénylindole (DAPI) was detected at 10–11 nm interval from 417 nm to 749 nm wavelength using a laser-scanning confocal microscope (Figure 3A). The presence of cyan fluorescence in multiple points of each GFP*TnI*Cx43+ cardiomyocyte was examined by using linear unmixing analysis (see Materials and Methods S1). Irrespective of the donor cell type, all 21 GFP+ cardiomyocytes detected in the cardiac tissues of 8 recipients coexpressed CFP (Figure 3B and 3C, see Table S2), suggesting that BM-derived cardiomyocytes are generated through cell fusion between BM-derived cells and recipient-derived cardiomyocytes.

Analysis of Cardiomyocyte-specific Genes in Mice Transplanted with Human Cord Blood HSCs

Finally, we aimed to clarify whether donor hematopoietic cells can change their cell fate through cell fusion with host cardiomyocytes. To this end, we set up xenogenic transplantation by injecting human cord blood-derived CD34+CD38− HSCs into immune-compromised mice (NOD/SCID/H2rγnull mice [23], NOD.Rag1nullH2rγnull mice [24], and C57BL/6.γC2nullH2rγnullNOD-Sirpa mice [25]). We extracted ribonucleic acid (RNA) from recipient cardiac tissues and performed quantitative real-time polymerase chain reaction (qRT-PCR) to detect human-specific cardiac transcription factors (Gata4 [GATA4], Tbx5 [Tbx5], Nkx2.5 [NKX2–5], and Mesp1 [MESP1]) [26] and cardiomyocyte structural genes (α-actinin heavy chain 6 [MYH6] and cardiac troponin C [TNNC1], connexin 43 [GJA1], and ryanodine receptor 2 [RYR2]). Of cardiac transcription factors, Gata4, Tbx5, and Mesp1 were not expressed in any of the examined 14 recipients. Although Nkx2.5 was expressed in 2 of
14 recipients, the expression of Nkx 2.5 was not specific to human cardiomyocytes since it was expressed in human cord blood [27] (see Table S3). Of cardiomyocyte structural genes, human myosin heavy chain 6 and troponin C were expressed in 1 of 14 and 9 of 14 recipients, respectively. Specificity of these probes to human cardiomyocytes was confirmed by the positive reaction to human cardiomyocytes.

Figure 2. Transplantation of HSCs and hematopoietic progenitors. (A) LSKs or CD34−LSKs were purified by FACS from Lin−/lowc-Kit+ BM fraction of GFP mice. GFP and Lineage−propidium iodide (PI) expression of unfractionated BM cells is shown as a control. (B) Total myeloid progenitors (My-P) and CLPs were purified by FACS from Lin−/lowThy1.2−/lowMNCs of GFP mice. (C-E) Correlational analyses between injected cell numbers and the numbers of GFP+ cardiomyocytes per a recipient mouse in recipients transplanted with Lin−/lowSca-1+ cells (C), LSKs (D), and CD34−LSKs (E). (F) Comparison of the number of GFP+ cardiomyocytes at the same injected cell dose in Lin−/lowSca-1+ cells, LSKs, and CD34−LSKs recipients. The means of the number of GFP+ cardiomyocytes in recipients transplanted with each injected cell number are plotted. In the transplantation of LSKs, injected cell number of 1–1.8×105 cells is plotted at 105, that of 1–4×104 cells is plotted at 104, and that of 1–2×103 cells is plotted at 103. The greater cardiomyogenic ability existed in CD34−LSKs than LSKs, and in LSKs than Lin−/lowSca-1+ cells.

doi:10.1371/journal.pone.0062506.g002
heart and the negative reaction to mouse heart and human cord blood. By contrast, ryanodine receptor 2 was not detected in any cardiac specimens derived from human HSC-engrafted recipients. Although connexin 43 was expressed in all of the recipients, the expression of connexin 43 was not specific to human cardiomyocytes since it was expressed in human cord blood consistent with previous reports showing connexin expression on several hematopoietic cells [28] (see Table S3). Although the frequency of cell fusion between donor hematopoietic cells and host cardiomyocytes is extremely low, we detected the cardiomyocyte-specific expression of the human cardiomyocyte structural gene, cardiac troponin C, but not that of other human cardiomyocyte structural genes such as ryanodine receptor 2 or human cardiac transcription factors in the cardiac tissue of recipient mice.

**Discussion**

We have obtained three findings by tracing the fate of genetically marked BM cells in vivo. First, HSCs generate cardiomyocytes along with hematopoietic reconstitution. Second, myeloid lineage cells are primary intermediates for cardiomyocyte generation. Third, cell fusion with recipient-derived cardiomyocytes is required for the generation of BM-derived cardiomyocytes. In this study, transplantation of cells derived from GFP-transgenic mouse into CFP-transgenic recipients enabled us to determine the mechanism for the generation of donor marker-positive cardiomyocytes. Moreover, confocal imaging and analyses for the separation of these two fluorescences led us to address the long-term question as to the issue of cell fusion or transdifferentiation.

Transplantation of purified HSCs to newborn syngeneic mice with cardiac injury resulted in the most frequent appearance of donor-marker+ cardiomyocytes in cardiac tissues. The results suggest the two possibilities, direct contribution of HSCs to cell fusion with cardiomyocytes and cell fusion between myeloid progeny and cardiomyocytes. Previous reports suggest that purified HSCs do not generate cardiomyocytes when directly transplanted into myocardium [10,20,21], but can generate cardiomyocytes following BM transplantation at a low frequency [4,10,12]. We have shown that cell fusion between BM-derived myeloid cells and host-derived cardiomyocytes results in the generation of donor-marker+ cardiomyocytes. The frequency of BM-derived cardiomyocytes in our study (~0.04%, see Materials and Methods S1) and other rodent studies (0.001–0.02%) [4,10,20] are similar to those of host marker-expressing cardiomyocytes in human cardiac transplantation (0.04–0.16%) [29,30], which may be the frequency of fusion between circulating myeloid cells from BM and cardiomyocytes in mammals in general.

Cells of myeloid lineage have been shown to contribute to skeletal myocytes [31,32], hepatocytes [33,34], or vascular endothelium [35] in vivo. We report here contribution of BM-derived myeloid progenitors to the generation of cardiomyocytes. Actually, several plasma membrane molecules related with cell

---

**Figure 3. CFP expression in the GFP+ BM-derived cardiomyocyte of a CFP-transgenic recipient mouse.** (A) Representative image of fluorescence detection from cardiac tissue of the CFP-transgenic recipient transplanted with GFP+ BM cells. Detected fluorescence images between 417 and 706 nm wavelength at 10–11 nm interval from a cardiac section stained with anti-TnI (Cy3), anti-Cx43 (Cy5), and DAPI are shown sequentially. (B) The expressions of DAPI, CFP, GFP, Cy3, and Cy5 in the cardiomyocyte shown in (A). Composition of GFP and CFP was examined simultaneously from each detected image between 449 and 663 nm wavelength (linear unmixing analysis). Detection wavebands used to visualize each fluorescence are described in each fluorescence image. The cardiomyocyte shown in (A) expressed donor-derived GFP, recipient-derived CFP, cardiac TnI, and Cx43. (C) Three dimensional analysis of the cardiomyocyte shown in (A) and (B) at the position of each nucleus. In every cross-section of three planes including nuclei, this cardiomyocyte expressed both GFP and CFP. Merged images (B and C) were obtained from the same confocal plane. Scale bars = 20 μm.

[doi:10.1371/journal.pone.0062506.g003](#)
fuson were up-regulated in myeloid lineage cells than lymphoid lineage cells confirmed by qRT-PCR (see Figure S3). Expression levels of integrin beta 1 [Igib1] or signal-regulatory protein alpha [Sirpa] in CMP were 1.73 or 1.92 fold higher than those in CLP, respectively (n = 3). Of the cells derived from GMPs, monocyotc cells are likely candidates as fusion partners since they have a physiological capacity for cell fusion [36]. Based on the finding that CD11b<sup>low</sup> cells, rather than CD11b<sup>high</sup> cells, within Gr-1<sup>−</sup>/low<sup>c-Kit</sup> BM fraction generated cardiomyocytes (unpublished observations), CD11b<sup>low</sup> immature monocytes may be the population contributing to the appearance of donor-marker<sup>+</sup> cardiomyocytes similar to the previous report describing the regeneration of skeletal muscle [32].

The number of donor-derived cells in recipient BM was very low following the transplantation of Lin<sup>−</sup>CD45<sup>−</sup> cells in our study (Table 1), consistent with previous studies [37,38]. Mesenchymal stem cells in the BM are considered to be relatively resistant to irradiation compared with HSCs [37,38]. Therefore, the lack of donor-derived cardiomyocytes following systemic infusion of Lin<sup>−</sup>/CD45<sup>−</sup> cells into sublethally irradiated mice may be due to inefficient engraftment of injected MSCs in the recipient BM. Intra-BM injection of 10<sup>5</sup> GFP-labeled clonally purified MSCs (CMG cells) resulted in the generation of donor-marker<sup>+</sup> cardiomyocytes [11]. Our results, together with the report showing little ability of MSCs to give rise to cardiomyocytes following intravenous or intramyocardial transplantation [9], imply that administration route and cell preparation need to be extensively assessed for cell therapy using MSCs. We examined whether BM-derived mesenchymal cells gain a cardiomyocyte phenotype through differentiation or cell fusion with a coculture experiment using GFP-expressing BM mesenchymal cells and adult cardiomyocytes. In the experiment, one GFP<sup>+</sup> cell expressing cardiomyocyte-specific antigens was detected (unpublished observations). However, the function of the cardiac-maker positive cell as a cardiomyocyte is unknown. A previous study demonstrated that mesenchymal stromal cell-derived cells acquiring cardiomyocyte phenotypic characteristics do not exhibit sufficient electrical property [39]. Additionally, improvement of cardiac function via mesenchymal stem/stromal cell transplantation is thought to be mediated by paracrine mechanism in addition to the direct contribution of cardiac marker-positive mesenchymal stem/stromal cells in themselves as contractile cardiomyocytes [40,41]. Recent report suggests that mesenchymal stromal cells recruit monocytes/macrophages secreting IL-10 or TGF-β [41]. Macrophages contributing to anti-inflammatory status could be one of the determinants for tissue regeneration in a mouse model for myocardial infarction [41]. Therefore, whether HSCs and MSCs act synergistically to regenerate cardiac tissue or to inhibit apoptosis in damaged cardiac tissue should be evaluated by using a large animal model in the future.

To establish regenerative medicine for heart failure patients, long-term improvement in cardiac function is important. Self-renewing cardiac-resident stem/progenitor cells [42,43] could maintain a pool for cardiomyocyte turnover [44,45]. BM could be one of the reservoirs that can give rise to cardiac-resident stem cells [46] and cells of multiple lineages [47]. Indeed, cardiomyocyte renewal in adult mammals is demonstrated under the physiological condition [48] or after injury [1]. Therefore, it should be demonstrated in the future to what degree BM-derived stem/progenitor cells and cardiac stem/progenitor cells contribute to turnover and regeneration of cardiomyocytes in the physiological or pathological conditions and whether BM-derived stem/progenitor cells can generate cardiac stem/progenitor cells.

Finally, we have demonstrated the contribution of myeloid lineage cells to cardiomyocytes through cell fusion. Recent reports suggest that stem cell fusion with the cardiomyocyte could add contractile function to the injured heart [49], and BM cell transplantation can restore impaired cardiac function [7]. Identification of the specific cell type and factors involved in cell fusion may lead to the enhancement of therapeutic effects of ongoing clinical cell therapy. In our qPCR analysis, two out of 6 donor cardiomyocyte-specific genes were detected in recipient cardiac tissues. Considering the low frequency of cell fusion, future experiments might be required to determine as to how far reprogramming process occurs following cell fusion. Altogether, our findings suggest that myeloid progenitors may potentially serve as a readily available source of effector cells for targeted cellular therapy of cardiac disorders through cell fusion.

Materials and Methods

Mice

C57BL/6 mice transgenically expressing enhanced GFP driven by the cytomegalovirus (CMV) enhancer/chicken β-actin promoter were kindly provided by Dr. M. Okabe (Osaka University). C57BL/6 mice transgenically expressing enhanced GFP driven by the CMV enhancer/chicken β-actin promoter, NOD/SCID/IL2r<sup>γc</sup><sup>−</sup>null mice, and NOD.Rag1<sup>−</sup>IL2r<sup>γc</sup><sup>−</sup>null mice were obtained from the Jackson Laboratory (Bar Harbor, ME). C57BL/6.Rag2<sup>−</sup>IL2r<sup>γc</sup><sup>−</sup>nullNOD-Sirpa mice were generated in our laboratory. All mice were bred and maintained under defined flora. Experiments were performed according to the guidelines approved by the Institutional Animal Committee of Kyushu University (Approval ID: 18–68). PB sampling from recipient mice was performed under deep inhalation anesthesia. BM and heart were dissected out from donor/recipient mice sacrificed by cervical dislocation under deep inhalation anesthesia.

Purification of Donor Cells

BM cells were harvested from GFP-transgenic mice at 8–12 weeks of age by flushing femurs and tibiae. MNCs were isolated by gradient centrifugation. Rat anti-mouse lineage antigen (BD Pharmingen, Caltag) and sheep anti-rat IgG antibody-conjugated immunomagnetic beads (Dynal) were used to deplete mature hematopoietic cells from MNCs. For separation of Lin<sup>−</sup>/CD45<sup>−</sup> cells and Lin<sup>−</sup>/CD45<sup>−</sup> cells and enrichment of Lin<sup>−</sup>/CD45<sup>−</sup> cells or Lin<sup>−</sup>/CD45<sup>−</sup> cells by magnetic cell sorting, immunomagnetic microbeads (Miltenyi Biotec) were used. For purification of each BM/stem/progenitor fraction by FACS, enriched BM cells were labeled by fluorescence-conjugated antibodies (see Materials and Methods S1). Umbilical cord blood cells were collected during normal full-term deliveries after obtained written informed consent (provided by Kyushu Block Red Cross Blood Center, Japan Red Cross Society). Experiments using cord blood were performed according to the guidelines approved by the Institutional Committee of Kyushu University (Approval ID: 17–114). MNCs were separated by Ficoll-Hypaque density-gradient centrifugation. Lineage-depleted cord blood cells were obtained magnetically (Miltenyi Biotec). Sorting of CD34<sup>+</sup>/CD38<sup>−</sup> subfractions was accomplished by staining lineage-depleted cord blood cells with fluorescein isothiocyanate (FITC)-conjugated anti-CD34, and phycoerythrin (PE)-conjugated anti-CD38 (BD Biosciences). Cell sorting was performed on a FACS aria (BD).

Transplantation

Unfractionated or purified BM cells from GFP mice were injected intravenously into C57BL/6 mice or GFP-transgenic mice.
within 48 hours of birth after 560 cGy irradiation. Left ventricular wall injury was induced by puncturing newborn recipient heart with a 29 G needle following transplantation of donor BM cells. Five to ten thousand Lin⁻/CD34⁺/CD38⁻ cells from human cord blood were transplanted into immune-compromised mice after irradiation.

Flow Cytometric Analysis of Recipient PB and BM

PB was collected from retro-orbital plexus of recipients, and BM cells were harvested from femurs and tibiaes. The percentage of GFP⁺ cells in PB and BM of recipients was examined by flow cytometric analysis using FACS Calibur (BD). PB and BM of recipients were labeled with each biotin-conjugated anti-mouse lineage antigen (CD3e, CD11b, B220, Gr-1, and TER-119) antibody, subsequently labeled with Cy3-conjugated streptavidin (Jackson ImmunoResearch) to recognize myeloid cells (CD11b, Gr-1), T lymphocytes (CD3ε), and B lymphocytes (B220) by flow cytometric analysis, FACS lysing solution (BD) was used to lyse red blood cells following antibody labeling.

Histological Analysis

Recipient hearts were removed and perfused with PBS to eliminate blood cells immediately after they were sacrificed by cervical dislocation. For immunofluorescence staining, recipient hearts were sectioned into 100-μm slices from apex to base with a vibratome (DTK-1000, D.S.K.) following fixation in 4% paraformaldehyde and dehydration in 70% ethanol. Vibratome-sectioned cardiac slices were stained with primary antibodies to CD45 (DakoCytomation), CD11b (BD Pharmingen), vimentin (Sigma), cardiac troponin I (Tni; Santa Cruz Biotechnology), and connexin43 (Cx43; Chemicon). Secondary antibodies conjugated with Cy3 or Cy5 (Jackson ImmunoResearch) were used to visualize primary antibodies. Forty contiguous cardiac sections per a recipient mouse were carefully examined for the presence of GFP⁺ cardiomyocytes by laser-scanning confocal microscopy (LSM-GB200, Olympus). In the transplantation of GFP⁺ BM cells into CFP-transgenic mice, linear unmixing analysis was employed to distinguish GFP⁺ cells into CFP-transgenic mice, linear unmixing analysis was performed by each biotin-conjugated anti-mouse lineage antigen (CD3e, CD11b, B220, Gr-1, and TER-119) antibody, subsequently labeled with Cy3-conjugated streptavidin (Jackson ImmunoResearch) to recognize myeloid cells (CD11b, Gr-1), T lymphocytes (CD3ε), and B lymphocytes (B220) by flow cytometric analysis, FACS lysing solution (BD) was used to lyse red blood cells following antibody labeling.

Quantitative Real-time Polymerase Chain Reaction

Total RNA was extracted from recipient heart, non-represent mouse heart, human cord blood, and 10⁶ cells each of sorted mouse hematopoietic cells. Reverse transcription was performed using SuperScript II or SuperScript III (Invitrogen) according to the manufacturer’s instructions. For human-specific cardiac transcription factors and cardiomyocyte structural genes, qRT-PCR was performed on the synthesized complementary deoxyribonucleic acid (cDNA) with Platinum Quantitative PCR Super-Mix (Invitrogen) on LightCycler 480 (Roche) to determine cycle threshold (Ct) of amplification. Human heart QUICK-Clone cDNA (Clontech) was used as a positive control. Human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the internal control. For mouse adhesion molecules, qRT-PCR was performed on Applied Biosystems 7500 real-time PCR system with TaqMan® primer-probe sets provided from Applied Biosystems. 18 s rRNA was used as the internal control. Sequences of dual-labeled fluorogenic probes and gene-specific primers (Sigma-Aldrich), and product ID of TaqMan® Gene Expression Assay (Applied Biosystems) are listed on Table S4. For initial normalization to the housekeeping gene, the difference in Ct value (∆Ct = [Ct gene of interest] – [Ct human GAPDH or 18 s rRNA]) was determined on each sample. Relative expression levels of each mRNA were calculated as the ratio to levels of human heart or mouse CLP cDNA using the comparative C_T (2⁻∆∆Ct) method [50].

Statistical Analysis

Results are presented as mean ± standard deviation (S.D.). Probability values were calculated by using the Mann-Whitney U test (non-parametric independent two-group comparison) or the Pearson’s correlation coefficient test. A probability value of less than 0.05 was considered to be statistically significant.

Supporting Information

Figure S1 Differentiation capacities of Lin⁻/lowCD45⁺ cells. (A) CD45 expression of Lin⁻/lowMNCs, separated Lin⁻/lowCD45⁺ cells, and separated Lin⁻/lowCD45⁻ cells. (B) Bright-field and fluorescence image of GFP⁺Lin⁻/lowCD45⁻ cells following culture. Polygonal or spindle-shaped adherent GFP⁺ cells were confirmed as mesenchymal cells. (C) In vitro differentiation of Lin⁻/lowCD45⁻ cells into osteoblasts (left) or adipocytes (right) by induction using differentiation media for each. Differentiation into osteoblasts or adipocytes was confirmed by alkaline phosphatase staining (left; red) or Oil red O staining (right; lipid vacuoles are stained in red), respectively. (D) Bone section of recipient transplanted with GFP⁺Lin⁻/lowCD45⁻ cells stained with anti-GFP (red, Cy3), anti-CD45 (yellow, Cy5), and DAPI (blue). Bright-field image is shown at leftmost. GFP⁺CD45⁻ cells were present within bone cortex (white arrows). These results suggest that separated Lin⁻/lowCD45⁻ cells contain MSCs that can differentiate into multiple mesenchymal lineages. Merged images were obtained from the same confocal plane. Scale bars = 20 μm. (TIF)

Figure S2 Flow cytometric analysis of recipient hematopoietic tissues. Representative image of flow cytometric analysis of recipient PB and BM transplanted with FACs-purified LSks, and recipient PB transplanted with total myeloid progenitors (Myp- or CLPs. In LSK recipients, donor-derived GFP⁺ myeloid cell lineage (Gbp1- or CD11b⁺), B cell lineage (B220⁺), and T cell lineage (CD3e⁺) were confirmed. Donor-derived myeloid cell lineage (Gbp1- or CD11b⁺) was predominantly present in recipients transplanted with total myeloid progenitors, and donor-derived B/T cell lineage (B220⁺ or CD3e⁺) was predominantly present in recipients transplanted with CLPs. (TIF)

Figure S3 Relative cDNA expression of adhesion molecules in myeloid and lymphoid lineages. The averages of relative cDNA expressions from three qRT-PCR experiments are indicated by histogram with positive standard deviation. Expression levels of Igfb1 and Sirpa in CMP were higher than those in CLP. Expression levels of Igfb1, Sirpa, and Adam9 in myeloid derivatives (neutrophil, monocyte) were higher than those in lymphoid derivatives (T lymphocyte, B lymphocyte). In the four adhesion molecules examined (Igfb1, Sirpa, Adam9, and Adam12), Adam12 was not detected in any of the samples. Gene names corresponding to each gene symbol, probes and primers information are described in Table S4. (TIF)

Table S1 The number of donor-derived cardiomyocytes after serial transplantation. (XLS)
Table S2 CFP expression of donor-derived GFP+ cardiomyocytes in CFP recipient mice.

Table S3 Relative cDNA expression to human heart.

Table S4 Probes and primers for quantitative real-time polymerase chain reaction (qRT-PCR).

Materials and Methods S1 Detailed information on purification of donor BM cells, cell culture and differentiation assay of Lin- /lowCD45- cells, and histological analysis.

References
1. Hsieh PC, Segers VF, Davis ME, MacGillivray C, Gannon J, et al. (2007) Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat Med 13: 970–974.

2. Dimmeler S, Zeiher AM, Schneider MD (2005) Unchaired heart: the scientific foundations of cardiac repair. J Clin Invest 115: 572–583.

3. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, et al. (2001) Bone marrow cells regenerate infarcted myocardium. Nature 410: 701–705.

4. Jackson KA, Majka MJ, Wang H, Pocius J, Hartley CJ, et al. (2001) Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 107: 1395–1402.

5. Schlaicher V, Erbs S, Elaasser A, Haberhosc B, Hambrecht R, et al. (2006) Intramyocellular bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 355: 1210–1221.

6. Meyer GP, Wollert KC, Lotz J, Steffens J, Lippolt E, et al. (2006) Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (Bone marrow cell transfer to enhance ST-elevation infarct reperfusion) trial. Circulation 113: 1287–1294.

7. Jeevanantham V, Butler M, Saad A, Abdel-Latif A, Zuba-Surma EK, et al. (2012) Adult bone marrow cell therapy improves survival and induces long-term improvements in cardiac parameters: a systematic review and meta-analysis. Circulation 126: 551–568.

8. Breitbach M, Bostani T, Roell W, Xia Y, Dewald O, et al. (2007) Potential risks of bone marrow transplantation into implanted hearts. Blood 110: 1362–1369.

9. Koide Y, Morikawa S, Mabuchi Y, Muguruma Y, Hiratsu E, et al. (2007) Two distinct stem cell lineages in murine bone marrow. Stem Cells 25: 1213–1221.

10. Nygren J, Vinge J, Breitbach M, Säwén P, Roll W, et al. (2004) Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat Med 10: 494–501.

11. Kawada H, Fujita J, Kinjo K, Matsuoka Y, Tsumida M, et al. (2004) Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 104: 3381–3387.

12. Ishikawa F, Shimazu H, Shultz LD, Fukata M, Nakamura R, et al. (2006) Purified human hematopoietic stem cells contribute to the generation of cardiomyocytes through cell fusion. FASEB J 20: 950–952.

13. Toma C, Pattengier MF, Callah KS, Byrne BJ, Kessler PD (2002) Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105: 93–98.

14. Teraoka N, Hamazaki T, Oka M, Hoki M, Mastalerz DM, et al. (2002) Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. Nature 416: 542–545.

15. Alvarez-Delgado M, Pardal R, Garcia-Veduga JM, Fike JR, Lee HO, et al. (2003) Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. Nature 425: 968–973.

16. Weimann JM, Johansson CB, Trejo A, Blasi HM (2003) Stable reprogrammed heterokaryons form spontaneously in Purkinje neurons after bone marrow transplantation. Nat Cell Biol 5: 959–966.

17. Herzog EL, Van Arnam J, Hu B, Zhang J, Chen Q, et al. (2007) Lung-specific nuclear reprogramming is accompanied by heterokaryon formation and Y chromosome loss following bone marrow transplantation and secondary inflammation. FASEB J 21: 2592–2601.

18. Jang YY, Collector MI, Baylin SB, Diehl AM, Sharkis SJ (2004) Hematopoietic stem cells convert into liver cells within days without fusion. Proc Natl Acad Sci U S A 101: 11507–11512.

19. Toma C, Pattengier MF, Callah KS, Byrne BJ, Kessler PD (2002) Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105: 93–98.

20. Murry CE, Sonpaa MH, Reinecke H, Nakajima H, Nakajima HO, et al. (2004) Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 429: 664–668.

21. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, et al. (2004) Haematopoietic stem cells adopt mature haematopoietic fates in ischemic myocardium. Nature 429: 668–673.

22. Cowboy IM, Cowboy MJ, Wagers AJ, Girrna ER, Weissman IL, et al. (2005) Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 433: 760–764.

23. Ishikawa F, Yasukawa M, Lyons B, Yoshiida S, Miyamoto T, et al. (2005) Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γchain(null) mice. Blood 106: 1563–1573.

24. Pearson T, Shultz LD, Miller D, King M, Lanning J, et al. (2008) Non-obese diabetic-recombination activating gene-1 (NOD-Rag1) null interleukin-2 receptor common gamma chain (IL2 gamma null) mice: a radiosensitive model for human lymphohematopoietic engraftment. Clin Exp Immunol 134: 270–281.

25. Yamauchi T, Takenaka K, Urata S, Shima T, Kikushige Y, et al. (2013) Polyomavirus Sirpa is the genetic determinant for NOD-based mouse lines to achieve efficient human cell engraftment. Blood 121: 1316–1325.

26. Bruneau BG (2002) Transcriptional regulation of vertebrate cardiac morphogenesis. Circ Res 90: 509–519.

27. Kucia M, Halasa M, Wyszynska M, Baskiewicz-Masik M, Mockenhauer S, et al. (2007) Morphological and molecular characterization of novel population of CXCR4+/SSEA-4+ Oct-4+ very small embryonic-like cells purified from human cord blood: preliminary report. Leukemia 21: 297–303.

28. Neijnen J, Pang B, Neefjes J (2007) Gap junction-mediated intercellular communication in the immune system. Prog Biophys Mol Biol 94: 207–218.

29. Laffamme MA, Myerson D, Saffite J, Murry CE (2002) Evidence for cardiomyocyte repopulation by extracardiac progenitors in transplanted human hearts. Circ Res 90: 634–640.

30. Muller P, Pfeiffer P, Kohlin J, Schafers HJ, Seeland U, et al. (2002) Cardiomyocytes of noncardiac origin in myocardial biopsies of human transplanted hearts. Circulation 106: 31–35.

Acknowledgments
We thank H. Fuji for excellent technical support on histological analysis of recipient cardiac tissue; N. Aoki for excellent technical support on histological analysis of recipient bone; S. Yoshida and C. Iwamoto for helpful advice; N. Kinukawa for helpful comments on statistical analysis.

Author Contributions
Discussion: MH KA. Conceived and designed the experiments: MF FI MH KA. Performed the experiments: MF FI YN YS KT KS KO K. Nakamura. Analyzed the data: MF FI YN YS KT BS KO K. Nagafuji. Contributed reagents/materials/analysis tools: TK K. Nakamura. Wrote the paper: MF FI YN YS.
42. Ferreira-Martins J, Opörek B, Cappetta D, Matsuda A, Signore S, et al. (2012) Cardiomyogenesis in the developing heart is regulated by c-kit-positive cardiac stem cells. Circ Res 110: 701–715.
43. Bu L, Jiang X, Martin-Puig S, Caron L, Zhu S, et al. (2009) Human ISL1 heart progenitors generate diverse multipotent cardiovascular cell lineages. Nature 460: 113–117.
44. Quaini F, Urbanek K, Beltrami AP, Finato N, Beltrami CA, et al. (2002) Chimerism of the transplanted heart. N Engl J Med 346: 5–15.
45. Genead R, Danielsson C, Andersson AB, Corbascio M, Franco-Cereceda A, et al. (2010) Isl1+ cells are cardiac progenitors present during the entire lifespan: from the embryonic stage to adulthood. Stem Cells Dev 19: 1601–1615.
46. Barile L, Cerisoli F, Frati G, Gaetani R, Chimenti I, et al. (2011) Bone marrow-derived cells can acquire cardiac stem cells properties in damaged heart. J Cell Mol Med 15: 63–71.
47. Kajstura J, Rota M, Whang B, Cascaperza S, Hosoda T, et al. (2005) Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion. Circ Res 96: 127–137.
48. Bergmann O, Bhardwaj RD, Bernard S, Zhune S, Barnabé-Heider F, et al. (2009) Evidence for cardiomyocyte renewal in humans. Science 324: 98–102.
49. Metzele R, Alt C, Bai X, Yan Y, Zhang Z, et al. (2011) Human adipose tissue-derived stem cells exhibit proliferation potential and spontaneous rhythmic contraction after fusion with neonatal rat cardiomyocytes. FASEB J 25: 830–839.
50. Schmitgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101–1108.